Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?
{{output}}
Background: We lack tools to predict treatment and survival outcomes in patients receiving additional BCG therapy as a bladder-preserving therapy in high grade/T1, Tis NMIBC patients who showed persistent/recurrent tumors at thre... ...
